CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $379,000 | +52.8% | 5,811 | +46.5% | 0.00% | +100.0% |
| Q1 2022 | $248,000 | -8.8% | 3,966 | +62.5% | 0.00% | 0.0% |
| Q3 2021 | $272,000 | -31.0% | 2,441 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $394,000 | +31.8% | 2,441 | -0.9% | 0.00% | 0.0% |
| Q1 2021 | $299,000 | -20.3% | 2,463 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $375,000 | +197.6% | 2,456 | +61.6% | 0.00% | +100.0% |
| Q3 2020 | $126,000 | -48.1% | 1,520 | -54.2% | 0.00% | 0.0% |
| Q2 2020 | $243,000 | +57.8% | 3,320 | +30.2% | 0.00% | 0.0% |
| Q1 2020 | $154,000 | 0.0% | 2,550 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $154,000 | +30.5% | 2,550 | -12.1% | 0.00% | 0.0% |
| Q3 2019 | $118,000 | -58.2% | 2,900 | -51.7% | 0.00% | 0.0% |
| Q2 2019 | $282,000 | +340.6% | 6,010 | +233.9% | 0.00% | – |
| Q1 2019 | $64,000 | +25.5% | 1,800 | 0.0% | 0.00% | – |
| Q4 2018 | $51,000 | -63.0% | 1,800 | -23.4% | 0.00% | -100.0% |
| Q2 2018 | $138,000 | – | 2,349 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |